Drug Search Results
More Filters [+]

Teniposide

Alternative Names: teniposide, vm-26, vm 26, vm26, vumon
Latest Update: 2024-11-18
Latest Update Note: Clinical Trial Update

Product Description

Teniposide is a semisynthetic derivative of podophyllotoxin with antineoplastic activity. Teniposide forms a ternary complex with the enzyme topoisomerase II and DNA, resulting in dose-dependent single- and double-stranded breaks in DNA, DNA: protein cross-links, inhibition of DNA strand religation, and cytotoxicity. This agent acts in the late S or early G phase of the cell cycle. (NCI04) (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Vumon)

Mechanisms of Action: TOP2 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Brazil | Canada | Chile | Colombia | Greece | Ireland | Italy | New Zealand | Peru | Portugal | Russia | Taiwan | Venezuela

Approved Indications: None

Known Adverse Events: None

Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Teniposide

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title